Novocure Ltd (NVCR) Director Sold $900,000.00 in Shares

Novocure Ltd (NVCR) Director Sold $900,000.00 in Shares

Novocure Ltd (NASDAQ:NVCR) Director Gabriel Leung sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 16th. The shares were sold at an average price of $45.00, for a total value of $900,000.00. Following the completion of the sale, the director now directly owns 80,000 shares of the company’s stock, valued at $3,600,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Gabriel Leung also recently made the following trade(s):

On Friday, January 25th, Gabriel Leung sold 20,000 shares of Novocure stock. The stock was sold at an average price of $50.00, for a total value of $1,000,000.00.

On Wednesday, January 9th, Gabriel Leung sold 20,000 shares of Novocure stock. The stock was sold at an average price of $40.00, for a total value of $800,000.00.

On Monday, December 10th, Gabriel Leung sold 5,000 shares of Novocure stock. The stock was sold at an average price of $33.49, for a total value of $167,450.00.

NASDAQ NVCR traded up $0.92 during midday trading on Monday, hitting $50.46. The company had a trading volume of 562,114 shares, compared to its average volume of 850,451. The stock has a market capitalization of $4.62 billion, a PE ratio of -72.09 and a beta of 3.25. The company has a debt-to-equity ratio of 1.30, a current ratio of 6.17 and a quick ratio of 5.72. Novocure Ltd has a twelve month low of $19.20 and a twelve month high of $53.70.

Several analysts recently weighed in on NVCR shares. Mizuho reissued a “buy” rating and set a $58.00 price target on shares of Novocure in a report on Friday, October 19th. ValuEngine cut Novocure from a “strong-buy” rating to a “buy” rating in a report on Friday, October 19th. Wedbush lifted their price target on Novocure from $55.00 to $58.00 and gave the stock an “outperform” rating in a report on Friday, October 26th. BidaskClub cut Novocure from a “buy” rating to a “hold” rating in a report on Saturday, October 27th. Finally, Wells Fargo & Co reissued a “market perform” rating and set a $36.00 price target (down from $41.00) on shares of Novocure in a report on Tuesday, October 30th. Three analysts have rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $48.00.

A number of hedge funds and other institutional investors have recently made changes to their positions in NVCR. Bank of New York Mellon Corp raised its holdings in Novocure by 83.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 365,923 shares of the medical equipment provider’s stock valued at $11,453,000 after acquiring an additional 166,834 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in Novocure by 30.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 133,900 shares of the medical equipment provider’s stock valued at $4,192,000 after acquiring an additional 31,300 shares in the last quarter. BlackRock Inc. raised its holdings in Novocure by 22.4% in the 2nd quarter. BlackRock Inc. now owns 4,620,546 shares of the medical equipment provider’s stock valued at $144,623,000 after acquiring an additional 846,277 shares in the last quarter. Legal & General Group Plc raised its holdings in Novocure by 35.1% in the 2nd quarter. Legal & General Group Plc now owns 27,726 shares of the medical equipment provider’s stock valued at $868,000 after acquiring an additional 7,203 shares in the last quarter. Finally, FMR LLC raised its holdings in Novocure by 12.6% in the 2nd quarter. FMR LLC now owns 7,862,121 shares of the medical equipment provider’s stock valued at $246,084,000 after acquiring an additional 881,776 shares in the last quarter. 58.63% of the stock is owned by hedge funds and other institutional investors.

Novocure Company Profile

Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St.

Recommended Story: How accurate is the Rule of 72?

Related posts

Leave a Comment